CRESCENT BIOPHARMA INC (CBIO) Stock Analyst Ratings
NASDAQ:CBIO - Nasdaq - US38000Q1022 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 84% to CBIO. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 26.18. This target is 96.99% above the current price.
CBIO was analyzed by 10 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about CBIO.
In the previous month the buy percentage consensus was at a similar level.
CBIO was analyzed by 10 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-07-14 | Wedbush | Initiate | Outperform |
| 2025-06-25 | Stifel | Initiate | Buy |
| 2025-06-18 | LifeSci Capital | Initiate | Outperform |
| 2021-11-15 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2021-08-06 | Raymond James | Maintains | Outperform |
| 2021-04-29 | Raymond James | Maintains | Outperform |
| 2021-02-10 | Piper Sandler | Initiate | Overweight |